Key Updates
British American Tobacco has declined -2.21% since the last report to £4,464, with YTD gains moderating to +5.93% from the previous +8.33%. The pullback follows the US International Trade Commission's opening of an investigation into illicit vaping products following BAT's Reynolds American subsidiary complaint. While this represents progress on BAT's multi-year battle against unauthorized vapes, the CEO previously indicated any material impact would be delayed until 2027 due to long supply chains and existing inventories. The recent weakness appears to reflect profit-taking after the strong February rally and broader market caution rather than fundamental deterioration.
Current Trend
BAT shares have consolidated recent gains, declining -3.33% over one day and -2.04% over five days, while maintaining positive momentum across longer timeframes (+2.01% over one month, +8.09% over six months). The YTD performance of +5.93% reflects a controlled pullback from the February peak of +10.63%, establishing a higher base around the £4,450-£4,500 range. The stock demonstrated resilience following strong 2025 full-year results on February 12, which showed pretax profit surging to £9.86 billion from £3.54 billion and adjusted operating profit exceeding consensus at £11.89 billion. The current consolidation phase appears technical rather than fundamental, with the stock digesting gains while maintaining support well above year-opening levels.
Investment Thesis
The investment thesis centers on BAT's dual-pillar strategy: extracting maximum cash flow from declining traditional tobacco volumes while scaling higher-margin next-generation products (NGPs) to offset structural volume declines. The company's New Categories division generated £3.62 billion in revenue with 7% constant-currency growth in 2025, while traditional operations continue delivering substantial operating leverage. Key thesis elements include: (1) market share gains in US nicotine pouches through Velo against Philip Morris's Zyn, (2) regulatory progress to eliminate the 70% illicit vape market share that undermines both traditional and NGP sales, (3) operational efficiency gains and portfolio optimization, including the closure of the South African factory due to 75% illicit market penetration, and (4) shareholder returns through a 2% dividend increase to 245.04 pence per share. The thesis assumes regulatory enforcement will eventually address illicit competition, unlocking significant value in BAT's authorized product portfolio.
Thesis Status
The investment thesis remains intact with incremental validation. The ITC investigation opening represents tangible progress on the regulatory enforcement pillar, though management's guidance suggests material benefits won't materialize until 2027. The 2025 results confirmed operational execution with £11.28 billion profit (+2.3%) and Velo gaining US market share through higher nicotine strengths and promotional strategies. However, competitive intensity is escalating, with Philip Morris achieving ahead-of-schedule growth targets and maintaining aggressive investment plans of up to $1.6 billion in smoke-free products. The South African factory closure underscores management's willingness to rationalize unprofitable operations rather than compete in dysfunctional markets. Near-term headwinds from illicit competition persist, but the regulatory trajectory and operational fundamentals support the medium-term thesis, albeit with extended timelines for value realization.
Key Drivers
Regulatory Enforcement Progress: The ITC probe into illicit vapes following Reynolds American's complaint against 16 companies represents the most significant regulatory development since the last report. BAT estimates unauthorized devices comprise 70% of US e-cigarette sales, and management projects a potential import block could reduce illegal sales by one-third, though implementation timing extends into 2027. An ITC judge previously ruled in BAT's favor in a patent dispute, recommending a general exclusion order.
Competitive Dynamics in Next-Generation Products: Philip Morris's 2026 guidance of 11.1%-13.1% EPS growth and $1.6 billion investment in smoke-free products intensifies competitive pressure. PMI's Zyn volumes grew 19% in Q4 but face market share losses to BAT's Velo, which gained ground through higher nicotine strengths and promotional offers. The appointment of experienced tobacco analyst Owen Bennett at BTIG signals sustained institutional focus on the sector's transformation dynamics.
Portfolio Rationalization: BAT's decision to close its South African factory by year-end, affecting 230 employees, reflects strategic discipline in markets where illicit trade (75% of cigarette sales) renders operations uneconomical. This follows years of government warnings about enforcement failures costing billions in excise revenue.
Raw Material Supply: Zimbabwe's record tobacco production of 360 million kilograms provides supply chain stability, with exports already up 64% YoY to 54.8 million kilograms, generating $399.8 million.
Technical Analysis
BAT shares are consolidating after establishing a February peak near £4,700, with the current price of £4,464 representing a -2.21% decline since the last report. The stock has formed a higher low structure, with support emerging around the £4,450 level compared to the previous base near £4,200. Short-term momentum indicators show weakness with consecutive daily declines (-3.33% over one day), but medium-term trends remain constructive with positive performance across one-month (+2.01%) and six-month (+8.09%) timeframes. The YTD gain of +5.93% positions the stock in the middle of its 2026 trading range, suggesting neither overbought nor oversold conditions. Volume patterns around the £4,450-£4,500 zone indicate accumulation interest, while resistance has formed at the £4,700 February high. The technical setup suggests a consolidation phase within an uptrend, with the 50-day moving average likely providing dynamic support. A break below £4,400 would signal deeper correction risk toward £4,200, while reclaiming £4,600 would target the prior £4,700 resistance.
Bull Case
- Regulatory Enforcement Catalyst: The ITC investigation into illicit vapes could eliminate one-third of the 70% unauthorized market share, potentially unlocking significant volume and margin recovery in BAT's authorized Vuse brand, with management expecting material impact in 2027.
- Strong Financial Performance and Shareholder Returns: 2025 pretax profit surged to £9.86 billion from £3.54 billion, with adjusted operating profit of £11.89 billion exceeding consensus estimates of £11.29 billion, while the company increased dividends 2% to 245.04 pence per share, demonstrating robust cash generation.
- Next-Generation Product Momentum: Velo nicotine pouches gained US market share against Philip Morris's Zyn through higher nicotine strengths and promotional strategies, with New Categories revenue growing 7% at constant currencies to £3.62 billion, establishing a £3.6+ billion revenue base in higher-margin products.
- Operational Discipline and Portfolio Optimization: The closure of the South African factory demonstrates management's willingness to exit unprofitable markets where illicit trade reaches 75%, reallocating resources to higher-return opportunities and improving overall portfolio profitability.
- Secured Raw Material Supply Chain: Zimbabwe's record 360 million kilogram tobacco production with exports up 64% YoY provides supply chain stability and potential cost advantages, with the continent's largest flue-cured tobacco producer ensuring reliable sourcing for BAT's traditional product portfolio.
Bear Case
- Intensifying Competitive Pressure in Growth Segments: Philip Morris forecasts 11.1%-13.1% EPS growth with up to $1.6 billion investment in smoke-free products, while PMI's Zyn maintains market leadership despite BAT's Velo gains, with PMI achieving three-year targets in just two years and smoke-free products reaching 41.5% of total revenues.
- Delayed Regulatory Benefits: Despite the ITC investigation opening, management indicated any material impact is unlikely before 2027 due to long supply chains and large existing inventories, extending the period of competitive disadvantage from the 70% illicit vape market share.
- Structural Volume Declines in Core Business: Overall group revenue declined 1% to £25.61 billion with a 3.1% foreign exchange headwind, while vape volumes fell nearly 13% in 2025 due to illegal product sales in the US and Canada, indicating persistent pressure on both traditional and next-generation product lines.
- Market Share Erosion in Key Geographies: The South African market deterioration to 75% illicit penetration necessitating factory closure demonstrates vulnerability to enforcement failures, with similar dynamics potentially threatening other emerging markets where BAT maintains significant operations and illicit trade undermines compliant producers.
- Extended Governance Concerns: Chair Luc Jobin's tenure extension beyond July 2026 will exceed the UK Corporate Governance Code's nine-year recommendation, as he has served since July 2017, potentially raising institutional investor concerns about board independence and succession planning during a critical transformation period.